AUSTIN, Texas--(BUSINESS WIRE)--Privately held On-X® Life Technologies Inc. (On-X LTI), whose mechanical heart valves have been implanted in more than 150,000 patients in over 90 countries, announced today that it has begun shipping its On-X Plus 1.5 Aortic Heart Valve to European hospitals. The early demand for the mechanical valve, particularly in Germany, Spain, Sweden, Finland and Greece, is a direct result of On-X LTI receiving European regulatory approval for an expanded labeling claim earlier this year. The new CE Mark permits the company to market its breakthrough valve in Europe with a reduced requirement for the use of the blood-thinning drug warfarin. The On-X™ Plus 1.5™ Aortic Heart Valve is the only approved mechanical heart valve that allows patients to be managed at an INR (International Normalized Ratio) range between 1.5—2.0. An INR blood test measures the time it takes for patients’ blood to clot.
Help employers find you! Check out all the jobs and post your resume.
